Last reviewed · How we verify
Ropivacaine 0.2% Injectable Solution
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgical procedures, Peripheral nerve blocks, Epidural anesthesia.
At a glance
| Generic name | Ropivacaine 0.2% Injectable Solution |
|---|---|
| Also known as | Naropin, 0.2% ropivacaine, Ropimol, Ropivacaine 2 mg/ml, iPACK + ACB |
| Sponsor | University of Minnesota |
| Drug class | Local anesthetic (amide class) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and nerve impulse transmission. This results in local anesthesia in the area of administration. As a long-acting amide local anesthetic, it has a slower onset and longer duration compared to shorter-acting agents like lidocaine.
Approved indications
- Local and regional anesthesia for surgical procedures
- Peripheral nerve blocks
- Epidural anesthesia
Common side effects
- Hypotension
- Bradycardia
- Nausea
- Dizziness
- Systemic toxicity (CNS and cardiac effects at high doses)
Key clinical trials
- Erector Spinae Plane Block for Acute Low Back Pain (NA)
- PENG Block Optimization: Volume and Dexamethasone Effects (PHASE4)
- Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults (NA)
- SII Levels Following PENG Block in Hip Arthroplasty (NA)
- PENG Block With Dexmedetomidine in Older Adults (NA)
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
- Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA (NA)
- PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0.2% Injectable Solution CI brief — competitive landscape report
- Ropivacaine 0.2% Injectable Solution updates RSS · CI watch RSS
- University of Minnesota portfolio CI